In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
Twenty patient associations from across northeastern Brazil are meeting in Fortaleza this month, inside a…
In 1968, a few joints I gave away left me facing the possibility of decades…
Here's the part that should worry every operator, investor, and vendor in the industry: this…
For one hash maker the clock starts at harvest, and the flower is in the…
Cannabis can absolutely take you somewhere that looks like a classic psychedelic experience. It just…
Researchers analyzing two ancient skeletons from Indonesia found dramatic dental wear and traces of arecoline,…